IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Radiotherapy
Tianjin Medical University Cancer Institute and Hospitalmonoclonal_antibodyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
39 Active assets in the Radiotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | B |
Toripalimab Northern Jiangsu People's Hospital | Phase 3 | B |
Eloxatin Tao Zhang | Phase 3 | B |
Nivolumab Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | B |
Capecitabine Tao Zhang | Phase 3 | B |
View all 42 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →